State of the German Shepherd.

Hip dysplasia is the most discussed orthopedic condition in this breed. The Oberbauer, Keller & Famula (2017) OFA registry analysis — roughly 107,000 German Shepherd hip evaluations from 1970 to 2015 — graded 18.9% of submitted radiographs as dysplastic, alongside 17.8% for elbow dysplasia. The figure is registry-based, so it has submission bias built in (responsible breeders submit; backyard breeders don’t); the true population rate is probably higher.

The financial consequence is severe: a bilateral total hip replacement can exceed $14,000 in the US, and most pet insurance policies impose a 6–12 month orthopedic waiting period specifically for this condition. Buying insurance the week before the diagnosis doesn’t work.

For the cost side of this, read German Shepherd hip dysplasia treatment cost — it walks through every surgical path from conservative management to bilateral total hip replacement, with insurance-coverage edge cases laid out.

For the full breakdown, see monthly cost and lifetime cost — both articles work through the line items: food, insurance, preventatives, grooming, training, vet visits, and the breed-specific risk-cost overlay.

EPI is the condition this breed is most disproportionately associated with in the veterinary literature. The Texas A&M GI Laboratory, which runs the TLI assay used to diagnose EPI worldwide, reports that roughly 42% of dogs diagnosed with the pancreatic-acinar-atrophy form of EPI are German Shepherds. That’s an extreme over-representation given how small a fraction the breed makes up of the general dog population.

What’s non-obvious: EPI in this breed isn’t a digestive disorder in the conventional sense. It starts as lymphocytic pancreatitis, an immune-mediated destruction of the enzyme-producing acinar cells. By the time clinical signs appear (chronic loose stools, ravenous appetite, weight loss despite eating), more than 90% of pancreatic function is already gone. Onset is typically between 1–5 years of age.

Westermarck’s 2010 heritability study on 42 GSD litters disproved the older assumption that EPI follows simple autosomal-recessive inheritance. Observed affected rates (~15%) sat well below the 25% expected for a simple recessive trait. The current best-supported model is polygenic, with MHC class II immune-regulation genes as risk modifiers.

Practical takeaway: EPI is lifelong but manageable. Pancreatic enzyme replacement (powdered porcine enzymes mixed into food) restores normal digestion, and most diagnosed Shepherds go on to live full lives once supplementation is dialed in.

The most-cited lifetime risk figure for GDV in large-breed dogs (about one in four) comes from Larry Glickman’s prospective cohort study at Purdue (JAVMA, 2000), which followed 1,914 dogs across 11 breeds for five years. Honest caveat: German Shepherds were not in the original cohort. The 24% figure is the average for the 23–45 kg bracket the breed falls into anatomically, not a direct measurement. It’s a defensible extrapolation, but it’s an extrapolation.

What’s striking is which risk factor proved strongest. Of all the variables Glickman tested, the single biggest predictor of GDV was thoracic depth-to-width ratio, a conformation trait baked into the breed standard. The second was first-degree relative history. Mortality even with prompt surgical intervention sits near 28.6%, which is why prophylactic gastropexy is a defensible discussion for at-risk dogs.

The two risk factors owners can actually modify are feeding speed and meal frequency: slow-feeder bowls and two or three smaller meals per day instead of one large one. The long-standing "raised bowls reduce bloat" recommendation was overturned by Glickman’s same study. Raised bowls actually increased risk in the cohort, a finding that took years to filter through the popular literature.

For the cost side (emergency surgery, gastropexy, ICU stay), see German Shepherd bloat surgery cost.

Degenerative myelopathy is this breed’s signature late-life neurological disease, and it has one of the best-characterized genetic backgrounds in canine medicine. In 2009, the Awano team at the University of Missouri identified the SOD1 c.118G>A point mutation in SOD1, strikingly homologous to a mutation that causes familial ALS in humans. The OFA database now holds genotype results on more than 15,000 Shepherds:

The critical nuance: being homozygous (A/A) doesn’t guarantee disease. Holder et al.’s UK study found that 16% of young, healthy GSDs were A/A, yet clinical DM typically doesn’t surface until around age 8, and many at-risk dogs never develop symptoms at all. That’s why the OFA grades A/A as "At Risk" rather than "Affected." Other genetic and probably environmental modifiers determine which at-risk dogs actually progress.

For breeders, a genetic test result is directly actionable: avoid A/A × A/A pairings. For pet owners, the result is informational. Most A/A Shepherds live full lives; for those that do progress, onset is late and progression is gradual over 6–24 months, hindlimb-first.